OTCMKTS:TBIO Telesis Bio (TBIO) Stock Price, News & Analysis $0.01 -0.03 (-74.09%) As of 10/30/2026 12:03 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisChartSEC Filings About Telesis Bio Stock (OTCMKTS:TBIO) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Telesis Bio alerts:Sign Up Key Stats Today's Range$0.01▼$0.0150-Day Range$0.00▼$0.0452-Week Range$0.00▼$0.15Volume100 shsAverage Volume147 shsMarket Capitalization$18 thousandP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Telesis Bio, Inc. develops automated synthetic biology systems designed to help researchers create and test biological molecules more efficiently. Its technology is intended to streamline the design-build-test process by automating tasks that traditionally require multiple manual laboratory steps. The company’s primary products include the BioXp automated benchtop platforms and related consumables, software, and application-specific kits. These systems support the on-demand synthesis and assembly of DNA, messenger RNA and other biological constructs for applications such as gene and cell therapy research, vaccine development, protein engineering, diagnostics and synthetic biology. Telesis Bio was formerly known as Codex DNA and changed its corporate name in 2023. The company markets its products to biotechnology and pharmaceutical companies, academic and government research institutions, and other life sciences organizations. Its platform is designed for use by customers in research and development laboratories in the United States and international markets. AI Generated. May Contain Errors. Read More Telesis Bio Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks28th Percentile Overall ScoreTBIO MarketRank™: 1.40812077043 of 5 starsTelesis Bio scored higher than 28% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's OpinionN/AAnalyst RatingN/A Consensus RatingThere is not enough analysis data for Telesis Bio. Earnings and Valuation0.0 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of Telesis Bio is 0.00, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Telesis Bio is 0.00, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Read more about Telesis Bio's valuation and earnings. Short Interest5.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted0.01% of the float of Telesis Bio has been sold short.Short Interest Ratio / Days to CoverTelesis Bio has a short interest ratio ("days to cover") of 0.17, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Telesis Bio has recently decreased by 53.98%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldTelesis Bio does not currently pay a dividend.Dividend GrowthTelesis Bio does not have a long track record of dividend growth. News and Social Media3.2 / 5News Sentiment1.16 News SentimentTelesis Bio has a news sentiment score of 1.16. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.65 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Telesis Bio this week, compared to 0 articles on an average week. Company Ownership1.2 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Telesis Bio insiders have not sold or bought any company stock.Percentage Held by Insiders24.50% of the stock of Telesis Bio is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions37.63% of the stock of Telesis Bio is held by institutions.Read more about Telesis Bio's insider trading history. Receive TBIO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Telesis Bio and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. TBIO Stock News HeadlinesTelesis Bio, Inc. (OTCMKTS:TBIO) Shares Shorted: Short Interest Down 54.0% in OctoberOctober 30 at 2:40 AM | americanbankingnews.comTelesis Bio, Inc. Common Stock (TBIO)May 14, 2026 | nasdaq.comA free stock pick, from me to youElon's paid this chip supplier since 2012. When NVIDIA tried to buy the company, he fought the deal. Without its chip, his AI satellites don't fly. Now he wants 1,000,000 of them in orbit, 100 times what's up there today, and every one pays this company a royalty. Dylan believes shares could react by December 8th.October 31 at 1:00 AM | Behind the Markets (Ad)Telesis Bio Inc.April 17, 2026 | barrons.comTelesis Bio Inc (TBIO) Stock Forums - Investing.comJune 29, 2025 | investing.comTelesis Bio Announces Licensing Agreement with Regeneron to Adopt Gibson SOLA™ Platform for Rapid On-Site DNA and Gene SynthesisMay 28, 2025 | finance.yahoo.comTelesis Bio Secures up to $21 Million to Accelerate Adoption of Groundbreaking Gibson SOLA Technology for Rapid DNA and mRNA SynthesisMarch 20, 2025 | finance.yahoo.comTelesis Bio Announces Departure of Chief Legal OfficerOctober 25, 2024 | markets.businessinsider.comSee More Headlines TBIO Stock Analysis - Frequently Asked Questions How have TBIO shares performed this year? Telesis Bio's stock was trading at $0.05 on January 1st, 2026. Since then, TBIO stock has decreased by 80.0% and is now trading at $0.01. How were Telesis Bio's earnings last quarter? Telesis Bio, Inc. (OTCMKTS:TBIO) released its quarterly earnings results on Monday, November, 8th. The company reported ($6.12) earnings per share for the quarter, missing analysts' consensus estimates of ($5.04) by $1.08. The business had revenue of $2.79 million for the quarter, compared to analyst estimates of $2.93 million. When did Telesis Bio's stock split? Telesis Bio's stock reverse split before market open on Thursday, May 9th 2024.The 1-18 reverse split was announced on Thursday, May 9th 2024. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, May 9th 2024. An investor that had 100 shares of stock prior to the reverse split would have 6 shares after the split. How do I buy shares of Telesis Bio? Shares of TBIO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Telesis Bio own? Based on aggregate information from My MarketBeat watchlists, some other companies that Telesis Bio investors own include Ford Motor (F), UiPath (PATH), Pfizer (PFE), Sunnova Energy International (NOVA), Corcept Therapeutics (CORT), GSI Technology (GSIT) and Lam Research (LRCX). Company Calendar Last Earnings11/08/2021Today10/31/2026Next Earnings (Estimated)11/17/2026Fiscal Year End12/31/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorHealthcare Industry Life Sciences Tools & Services Sub-IndustryLife Sciences Tools & Services Current SymbolOTCMKTS:TBIO Previous SymbolNASDAQ:TBIO CIK1850079 Webtelesisbio.com Phone858-228-4115FaxN/AEmployees200Year Founded2013Profitability EPS (Trailing Twelve Months)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual Sales$27.51 million Price / Sales0.00 Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding Shares1,800,000Free Float1,361,000Market Cap$18 thousand OptionableNo Data Beta2.58 Social Links 7 Stocks to Buy Before the Robotics RevolutionRobotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries. "Physical AI" is coming. Learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.Get This Free Report This page (OTCMKTS:TBIO) was last updated on 10/30/2026 by MarketBeat.com Staff. From Our PartnersFinancial legend: “This is bad, really bad...”Dr. Martin D. Weiss has publicly predicted six major American market crashes over his 55-year career, each war...Weiss Ratings | SponsoredCigar Lake Flooded Again Uranium Supply Shock RepeatsIn 2006, a flooded mine at Cigar Lake sent uranium prices from the 50 range to 136 in eight months. This pa...Digest Publishing | SponsoredThe investigation Porter spent tens of thousands to documentPorter Stansberry flew the Porter and Co. team 3,300 miles to Dublin to investigate a 17-year investing experi...Porter & Company | SponsoredA free stock pick, from me to youElon's paid this chip supplier since 2012. When NVIDIA tried to buy the company, he fought the deal. Withou...Behind the Markets | SponsoredLast note from me on thisJoel Peterson's free workshop breaks down a three step, three color system that works across stocks, ETFs, gol...The Cycle Code | SponsoredWhat Elon Musk's Cybercab Reveal Could Mean for InvestorsJeff Brown, the analyst who flagged Bitcoin, Tesla, and Nvidia early, is tracking Elon Musk's next move. He po...Brownstone Research | SponsoredLast call for your free 0DTE reportThe 0DTE Game Plan lays out a simple 3-step framework for trading same-day options: Plan it, profit from it, p...Profits Run | SponsoredDon't lose access to thisIan Cooper's guide, 'The $50-to-$500 Options Strategy,' is still available for free download, but not for long...TradeWins | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Telesis Bio, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Telesis Bio With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
